Molecular Therapy Nucleic Acids is a premier open-access journal published by CELL PRESS, dedicated to advancing the field of molecular medicine through the innovative application of nucleic acid-based therapies. Since its inception in 2012, this journal has become an essential resource for researchers and professionals in drug discovery and molecular medicine, reflected in its status as a Q1 journal in both categories for 2023. With a notable impact factor and high rankings in Scopus, including #8 out of 157 in Drug Discovery and #16 out of 178 in Molecular Medicine, it serves to disseminate groundbreaking research and foster collaborations among scientists worldwide. The journal's comprehensive scope encompasses a wide variety of topics, including gene therapy, RNA interference, and CRISPR technology, ensuring that it remains at the forefront of scientific excellence. With open access availability, Molecular Therapy Nucleic Acids actively promotes the widespread dissemination of knowledge, making its crucial insights accessible to students, researchers, and industry professionals alike.

Journal of Clinical Lipidology, published by Elsevier Science Inc, is a leading platform dedicated to advancing the understanding of lipidology and its impact on cardiovascular health. With an ISSN of 1933-2874 and E-ISSN 1876-4789, this esteemed journal boasts a remarkable Q1 ranking in key medical categories, including Cardiology and Cardiovascular Medicine, Internal Medicine, and Nutrition and Dietetics, solidifying its position as a vital resource for the latest research and clinical practices. This journal not only serves as a repository for groundbreaking studies but also provides insights into complex interactions between lipid metabolism and chronic diseases, including diabetes and obesity. Researchers, practitioners, and students will find a wealth of carefully vetted articles that drive innovation and improve patient outcomes in lipid management. Although it does not currently offer open access, the Journal of Clinical Lipidology ensures high visibility through rigorous peer review and a commitment to quality, making it an essential read for anyone invested in the future of lipidology.

EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, published by WILEY, is a reputable academic journal dedicated to advancing the field of lipid science and technology. With an ISSN of 1438-7697 and E-ISSN 1438-9312, this journal serves as a critical resource for researchers, professionals, and students interested in the bioengineering, industrial applications, and nutritional science of lipids. Covering a broad spectrum from biochemistry to food science, it holds distinguished rankings across multiple categories, including Q2 in Chemistry and Food Science, and Q3 in Biotechnology, showcasing its significance in the interdisciplinary study of lipids. The journal welcomes Open Access options, fostering the dissemination of knowledge and innovation in lipid research. With converged years extending from 2000 to 2024, this journal remains at the forefront of lipid-related research, encouraging scholarly contributions that push the boundaries of science and technology.

LIPIDS is a renowned peer-reviewed journal published by Wiley, dedicated to the field of lipid research, encompassing biochemistry, molecular biology, and organic chemistry. With its roots dating back to 1966 and a commitment to advancing knowledge until 2024, this journal serves as a vital platform for sharing significant findings in lipid biochemistry and its applications in health and disease. Although it currently does not offer Open Access options, it maintains a respectable standing with a Q3 ranking in Biochemistry and Organic Chemistry, and a Q4 ranking in Cell Biology based on the 2023 category quartiles. Additionally, its Scopus rankings reflect a solid position within the organic chemistry and biochemistry subfields. Published from Germany, LIPIDS caters to researchers, professionals, and students eager to explore the roles of lipids in biological processes and innovatory applications in various scientific disciplines.

Nature Metabolism, published by NATURE PORTFOLIO, is a leading journal dedicated to advancing the field of metabolic research and its implications across various biological systems. Since its inception in 2019, this esteemed journal has rapidly established itself as a vital resource for researchers, professionals, and students alike, reflecting its prominence through a prestigious Q1 ranking in several key categories including Cell Biology, Endocrinology, Diabetes and Metabolism, Internal Medicine, and Physiology. With an impressive Scopus ranking, underscoring its impact in Medicine and Biochemistry disciplines, Nature Metabolism offers an exceptional platform for disseminating high-quality research that explores the intricate mechanisms of metabolism and its association with health and disease. Although currently not open access, it continues to gain visibility and appreciation within the scientific community, ensuring that groundbreaking findings reach interested audiences globally from its hub in Berlin, Germany. Whether you are an experienced researcher or an aspiring student, Nature Metabolism serves as an invaluable asset in navigating the complexities of metabolic science.

Welcome to BIOCHIMIE, a prestigious journal dedicated to advancing the field of biochemistry and related areas of medicine. Published by Elsevier France - Editions Scientifiques Medicales Elsevier, this journal has been a cornerstone of scientific communication since its inception in 1971 and will continue to contribute essential research until 2024. With an impressive impact factor and categorized in Q2 for Biochemistry and Q1 for Miscellaneous Medicine, BIOCHIMIE ranks among the top quartiles in its fields, underscoring its significance and influence in the scientific community. Targeting a wide audience of researchers, professionals, and students, the journal publishes high-quality articles that explore innovative research and developments in biochemistry, genetics, and molecular biology, reflected in its Scopus ranking of 136 out of 438 in the biochemistry category. Despite its traditional publication format, the journal remains committed to promoting impactful research that drives the future of biochemistry and molecular medicine, ensuring that readers have access to critical insights that foster advancements in health and science.

PPAR Research, an esteemed journal published by HINDAWI LTD, specializes in the rapidly evolving fields of drug discovery and pharmacology, contributing significantly to the body of research surrounding peroxisome proliferator-activated receptors (PPARs) and their roles in various biochemical processes. With an open access policy implemented since 2006, the journal ensures that its high-quality content is readily available, promoting widespread dissemination of knowledge. Currently ranked in the Q2 category for both Drug Discovery and Medical Pharmacology, it boasts a respectable position within the scientific community, evidenced by its Scopus rankings. PPAR Research serves as an essential resource for researchers, professionals, and students looking to advance their understanding of PPAR biology and its implications in therapeutic development. The journal's commitment to excellence and accessibility makes it a key player in supporting innovative research and critical discussions in the life sciences.

PROSTAGLANDINS & OTHER LIPID MEDIATORS, published by Elsevier Science Inc, is a leading journal dedicated to the advancements in the field of lipid mediators, with a specific focus on prostaglandins and other bioactive lipids. This journal, indexed under ISSN 1098-8823 and E-ISSN 2212-196X, serves as a crucial platform for researchers and professionals to disseminate significant findings that span multiple disciplines, including Biochemistry, Cell Biology, Pharmacology, and Physiology. In the 2023 category quartiles, it has achieved commendable positions such as Q2 in Biochemistry and Q2 in Physiology, underscoring its importance and influence in these domains. Although it is not an open-access journal, it provides robust access options, enhancing the visibility of vital research. With its establishment in 1996, the journal continues its commitment to fostering innovative research until 2024, making it an essential resource for those involved in the dynamic realms of lipid biology and medical research.

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES is a prestigious journal dedicated to advancing the field of biomembrane research, published by Elsevier. With a notable track record since its inception in 1967, this journal operates under the dual ISSN 0005-2736 and E-ISSN 1879-2642, and has firmly established itself within the scientific community by ranking in the top tiers of various disciplines, including Q2 in Biochemistry and Cell Biology, and Q1 in Biophysics as of 2023. Its impressive Scopus rankings further underscore its importance, with a rank of 24 in Biophysics reflecting its strong impact on ongoing research. Although it does not offer open access, the journal provides comprehensive insights and breakthroughs essential for scientists, researchers, and advanced students focused on biophysical and biochemical aspects of membranes. By disseminating pivotal findings, BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES contributes significantly to understanding cellular mechanisms, thereby serving as a vital resource for professionals aiming to explore the complexities of biological membranes.

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS is a distinguished peer-reviewed journal dedicated to advancing the understanding of the biological roles of prostaglandins, leukotrienes, and essential fatty acids in human health and disease. Published by Elsevier Science Ltd, this journal has been at the forefront of research since its inception in 1988 and continues to serve as a vital resource for researchers, clinicians, and students involved in the fields of biochemistry and cell biology. With its impact factor reflecting a solid academic presence—ranking Q3 in Cell Biology and Q2 in Clinical Biochemistry in 2023—this journal is recognized for its quality contributions, particularly in uncovering the biochemical pathways and clinical implications of these lipid mediators. Though not an open-access journal, it provides various access options to ensure the dissemination of critical findings. As the field evolves, PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS remains a pivotal platform for the exploration and discussion of new methodologies, therapeutic avenues, and biological discoveries that impact patient care and the foundational sciences.